You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
SPRAVATO is indicated for treatment resistant depression (Major Depressive Disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode).,SPRAVATO is to be initiated in conjunction with a newly initiated oral antidepressant.
Clear colourless to slightly yellowish aqueous solution packaged in Type 1 glass vial, rubber stopper and assemble inside a single use nasal spray device
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
SPRAVATO is indicated for treatment resistant depression (Major Depressive Disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode).,SPRAVATO is to be initiated in conjunction with a newly initiated oral antidepressant.
Clear colourless to slightly yellowish aqueous solution packaged in Type 1 glass vial, rubber stopper and assemble inside a single use nasal spray device
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
SPRAVATO is indicated for treatment resistant depression (Major Depressive Disorder in adults who have not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode).,SPRAVATO is to be initiated in conjunction with a newly initiated oral antidepressant.
Clear colourless to slightly yellowish aqueous solution packaged in Type 1 glass vial, rubber stopper and assemble inside a single use nasal spray device
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
